Bioscribe is a full-service communications consultancy focused on the life sciences sector. It provides custom communications programs for companies at various growth stages, offering services such as corporate communications, media strategy and public relations, social media management, content development, events organization, advocacy, and marketing communications. Bioscribe works with biotechnology and life science innovators.

Bioscribe

Biotechgate provides information and solutions for the life sciences industry, including databases for clinical trials and investor connections. The service offers access to business development and licensing information self-described as comprehensive.

Biotechgate

Bioscribe | 621 followers on LinkedIn. Let us help you tell your story. | Bioscribe was founded in 1997 in the San Francisco Bay Area to support the area&#39;s growing biotechnology industry. For more than two decades, we have worked with companies that powered the Human Genome Project and cutting-edge start-ups that are innovating to unlock its value. We&#39;ve helped launch first, second and third generation DNA sequencing systems, gene expression tools, bioinformatics software, single cell analysis solutions, molecular diagnostics, DNA forensics systems, next-generation therapies, and vaccines.

CEO of Bioscribe, Inc. - Life Sciences Communications Agency

Nicole Litchfield

Marketing and Communications

Andrew Noble

Strategic Healthcare Integrated Marketing Communications Executive | Public Relations | Global Media Relations Professional | Pharma & Biotech | Life…

Nancie Steinberg

Life Science Communications Consultant

Tim Ingersoll

Congratulations to the Vizgen team for securing the #1 private company spot on Genetic Engineering & Biotechnology News ' 2024 list of Top Spatial Biology Companies! Bioscribe is honored to partner with this innovative team and we are excited to support their continued success in 2025 and beyond! #InnovativeClients #ClientNews #PR #LifeScienceComms #LifesScienceMarketing #Biotech #LifeSciences

The trade media are often considered second fiddle to the buzzier top-tier outlets, but they are by no means less important to your overall earned media strategy. After 27 years working in the life sciences industry, the Bioscribe team has seen time and time again how this kind of targeted exposure is a perfect complement to the higher-profile articles placed in the top-tier media, allowing you to sustain momentum and credibility among key decision-makers and influencers. Read more about the 5 reasons why we believe that trade journalists, with their deeper understanding of the industry’s inner workings, can provide sophisticated and nuanced coverage that resonates with the often skeptical life science-focused audiences. #PR #MediaRelations #SciComms #BiotechPR #LifeSciencePR

Complex DNA is, in a word, complex. This excellent primer from Ansa co-founder & CSO, Dan Lin-Arlow, breaks it down and highlights how enzymatic DNA synthesis is paving the way forward for the complex DNA that is essential to driving innovation in the bioeconomy. #SynBioBeta2024 #InnovativeClients

PR tip: Don't forget to showcase your company's small wins between big milestones ⬇ Read more PR perspectives from Nicole Litchfield , CEO and founder of our partners at Bioscribe , in the latest issue of The Pitch: https://lnkd.in/gnyPWtiA

s2s Public Relations

Today we announced a partnership with s2s Public Relations , based in Seattle. From first working together on a co-marketing campaign seven years ago, to our new partnership announced today, it’s been a pleasure getting to know Eric Schudiske and his team. For more than 25 years, Bioscribe has been a trusted partner to the life sciences startup community, and advisor to founders, CEOs, VCs, commercial teams, and comms leaders who are shaping the future of innovation and the bioeconomy. We are excited about our new partnership with s2s because it broadens our bench with new talent and capabilities in ways that will benefit our individual and shared clients, as well as our teams! #teamwork #entrepreneurship #lifescience #scicomms #biotechPR

Thanks to Dani Stoltzfus and William Riedl at Mighty Spark Communications for hosting an engaging conversation with Bioscribe EVP Colin Sanford about when to consider the help of professional PR counsel. It's a question we get often, and one we are always happy to discuss. In a nutshell, the decision to enlist help extends beyond an approaching milestone. It's about strategically orchestrating your PR and communications programs to align with your near-term goals while fostering a platform for building and maintaining ongoing momentum for your long-term vision. If you're seeking support for the first time, or looking for ways to expand your existing PR and communications programs, please reach out for a free consultation. We'd be happy to share our perspectives on strategies that will help you successfully engage with all of your audiences today, and into the future. #biotechpr #lifesciencePR #scicomms #publicrelations #biotech

Big congratulations to the Synthego & EditCo teams on this industry-advancing milestone that will further accelerate innovation in the discovery and development of cell and gene therapies! #CRISPR #LifeSciences #Biotech #SciComm #CoolClients

Team Bonum Therapeutics has an incredible track record in biopharmaceutical dealmaking. In this insightful perspective, Chief Business Officer Neela Patel shares advice on navigating win-win negotiations that get you to the deal you want! #ThoughtLeadership #SmartClients

Congratulations to long-time Bioscribe client and friend Jason T. Gammack who has been appointed CEO of Ansa Biotechnologies, Inc. . Ansa is developing a new way to synthesize DNA that overcomes the limitations of traditional DNA synthesis methods to enable innovation across biologic therapeutics such as antibodies, gene therapies, and cell therapies, as well as the biomanufacturing of chemicals, materials, foods, and biofuels. https://lnkd.in/gQDUYqUu #CoolScience #AwesomeClients

In this Biocompare piece, client ATUM talks about how they leverage machine learning to power a directed engineering approach that enables them to determine the relationship between protein sequence and properties of interest and then use those insights to drive the engineering of improved variants. #biotech #proteinengineering #scienceiscool

Metric
Company Name	Bioscribe	Biotechgate
Symbol
MSH ID	COM:BIOSCRIBE	COM:BIOTECHGATE
Market	PRIVATE	PRIVATE
Sector	Commercial & Professional Services	Commercial & Professional Services
Industry	Public Relations	Life Sciences
Country	US	CH
Stage
Employee Count
Website	bioscribe.com	biotechgate.com
LinkedIn	bioscribe	biotechgate
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic		2.80K
Web Traffic Growth		2.27
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

BIOS

COM:BIOSCRIBE

Bioscribe

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue